Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Merck KGaA (FSE:MRK) said that following a portfolio review of subsidiary Merck Serono's pipeline, the company will focus R&D activities on cancer, neurodegenerative
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury